Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 8/2017

02.03.2017 | Review

Health-related quality of life in patients receiving long-term opioid therapy: a systematic review with meta-analysis

verfasst von: J. Douglas Thornton, Rashmi Goyat, Nilanjana Dwibedi, George A. Kelley

Erschienen in: Quality of Life Research | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Over 25 million Americans reported having daily pain and between 5 and 8 million Americans used opioids to treat chronic pain in 2012. This is the first systematic review with meta-analysis to determine the effects of long-term opioid use on the Physical Component Summary (PCS) score and Mental Component Summary (MCS) scores of a Health-Related Quality of Life instrument in adults without opioid use disorder.

Methods

The a priori eligibility criteria for the PubMed (MEDLINE), Scopus, and PsyINFO searches were (1) randomized controlled trial, (2) at least one opioid intervention group, (3) minimum of 4-week duration of opioid use, (4) comparative control group, and (5) adults ≥18 years that do not have dominant disease. The unit of analysis was the standardized mean difference effect size (Hedges’s g). All results were pooled using random-effects models.

Results

Of the 340 non-duplicate citations screened, 19 articles comprising 26 treatment comparisons and 6168 individuals (treatment n = 3160; comparators n = 3008 with duplicates removed) met the inclusion criteria for the systematic review. Thirteen treatment comparisons were available for the meta-analysis. Across all PCS analyses, small, statistically significant improvements were observed (opioid versus opioid only: g = 0.27, 95% CI 0.05–0.50, opioid versus placebo only: g = 0.18, 95% CI 0.08–0.28, and all studies combined: g = 0.22, 95% CI 0.11–0.32). There were small but not statistically significant changes on the MCS scores. Overall, high heterogeneity was present.

Conclusions

PCS scores improve with no change in MCS scores. However, long-term opioid trials are rare and only two trials included lasted longer than 1 year.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Ballantyne, J. C., & Shin, N. S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. The Clinical Journal of Pain, 24(6), 469–478.CrossRefPubMed
2.
Eriksen, J., Sjogren, P., Bruera, E., Ekholm, O., & Rasmussen, N. K. (2006). Critical issues on opioids in chronic non-cancer pain: An epidemiological study. Pain, 125(1–2), 172–179.CrossRefPubMed
3.
Institute of Medicine. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press
4.
Gaskin, D. J., & Richard, P. (2012). The economic costs of pain in the United States. The Journal of Pain: Official Journal of the American Pain Society, 13(8), 715–724.CrossRef
5.
Nahin, R. L. (2015). Estimates of pain prevalence and severity in adults: United States, 2012. The Journal of Pain: Official Journal of the American Pain Society, 16(8), 769–780.CrossRef
6.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008). Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Experimental and Clinical Psychopharmacology, 16(5), 405–416.CrossRefPubMedPubMedCentral
7.
8.
Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States. JAMA, 315, 1624–1645.CrossRefPubMed
9.
10.
11.
Centers for Disease Control and Prevention. (2011). Vital signs: Overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR: Morbidity and Mortality Weekly Report, 60(43), 1487–1492.
12.
Zgierska, A., Miller, M., & Rabago, D. (2012). Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA: The Journal of the American Medical Association, 307(13), 1377–1378.CrossRefPubMed
13.
Ballantyne, J. C., & Mao, J. (2003). Opioid therapy for chronic pain. The New England Journal of Medicine, 349(20), 1943–1953.CrossRefPubMed
14.
15.
Coons, S. J., Rao, S., Keininger, D. L., & Hays, R. D. (2000). A comparative review of generic quality-of-life instruments. Pharmacoeconomics, 17(1), 13–35.CrossRefPubMed
16.
Cook, D. J., Mulrow, C. D., & Haynes, R. B. (1997). Systematic reviews: Synthesis of best evidence for clinical decisions. Annals of Internal Medicine, 126(5), 376–380.CrossRefPubMed
17.
Garg, A. X., Hackman, D., & Tonelli, M. (2008). Systematic review and meta-analysis: When one study is just not enough. Clinical Journal of the American Society of Nephrology, 3(1), 253–260.CrossRefPubMed
18.
Skelly, A. C. (2014). Credibility matters: Mind the gap. Evid Based Spine Care Journal, 5(1), 2–5.CrossRef
19.
De Maeyer, J., Vanderplasschen, W., & Broekaert, E. (2010). Quality of life among opiate-dependent individuals: A review of the literature. International Journal on Drug Policy, 21(5), 364–380.CrossRefPubMed
20.
Ekstrom, M., Nilsson, F., Abernethy, A. A., & Currow, D. C. (2015). Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Annals of the American Thoracic Society, 12(7), 1079–1092.CrossRefPubMed
21.
Thakur, D., Dickerson, S., Kumar Bhutani, M., & Junor, R. (2015). Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients’ daily functioning in comparison with extended-release tapentadol: A systematic review. Clinical Therapeutics, 37(1), 212–224.CrossRefPubMed
22.
Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 339, b2700.CrossRefPubMedPubMedCentral
23.
Afilalo, M., & Morlion, B. (2013). Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician, 16(1), 27–40.PubMed
24.
Baron, R., Jansen, J. P., Binder, A., et al. (2015). Tolerability, safety, and quality of life with tapentadol prolonged release (pr) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, phase 3b/4 trial. Pain Practice. doi:10.​1111/​papr.​12361.
25.
Bennett, R. M., Schein, J., Kosinski, M. R., Hewitt, D. J., Jordan, D. M., & Rosenthal, N. R. (2005). Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatism, 53(4), 519–527.CrossRefPubMed
26.
Binsfeld, H., Szczepanski, L., Waechter, S., Richarz, U., & Sabatowski, R. (2010). a randomized study to demonstrate noninferiority of once-daily OROS® hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Practice: The Official Journal of World Institute of Pain, 10(5), 404–415.CrossRef
27.
Gajria, K., Kosinski, M., Schein, J., Kavanagh, S., & Dubois, D. (2008). health-related quality-of-life outcomes in patients treated with push-pull OROS hydromorphone versus Extended-release oxycodone for chronic hip or knee osteoarthritis pain: A randomized, open-label, parallel-group, multicenter study. The Patient, 1(3), 223–238.CrossRefPubMed
28.
Gordon, A., Callaghan, D., Spink, D., et al. (2010). Buprenorphine transdermal system in adults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clinical Therapeutics, 32(5), 844–860.CrossRefPubMed
29.
Kalso, E., Simpson, K. H., Slappendel, R., Dejonckheere, J., & Richarz, U. (2007). Predicting long-term response to strong opioids in patients with low back pain: Findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Medicine, 5, 39.CrossRefPubMedPubMedCentral
30.
Allan, L., Richarz, U., Simpson, K., & Slappendel, R. (2005). Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine, 30(22), 2484–2490.CrossRefPubMed
31.
Karlsson, M., & Berggren, A. C. (2009). Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: A 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clinical Therapeutics, 31(3), 503–513.CrossRefPubMed
32.
Khoromi, S., Cui, L., Nackers, L., & Max, M. B. (2007). Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain, 130(1–2), 66–75.CrossRefPubMed
33.
Ma, K., Jiang, W., Zhou, Q., & Du, D. P. (2008). The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients. International Journal of Clinical Practice, 62(2), 241–247.CrossRefPubMed
34.
Miller, K., Yarlas, A., Wen, W., et al. (2013). Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opinion on Pharmacotherapy, 14(3), 269–277.CrossRefPubMed
35.
Nicholson, B., Ross, E., Sasaki, J., & Weil, A. (2006). Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Current Medical Research and Opinion, 22(8), 1503–1514.CrossRefPubMed
36.
Pedersen, L., Borchgrevink, P. C., Breivik, H. P., & Fredheim, O. M. (2014). A randomized, double-blind, double-dummy comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain. Pain, 155(5), 881–888.CrossRefPubMed
37.
Peloso, P. M., Fortin, L., Beaulieu, A., Kamin, M., & Rosenthal, N. R. (2004). Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet®) in treatment of chronic low back pain: A multicenter, outpatient, randomized, double blind, placebo controlled trial. The Journal of Rheumatology, 31(12), 2454–2463.PubMed
38.
Rauck, R. L., Bookbinder, S. A., Bunker, T. R., et al. (2007). A randomized, open-label, multicenter trial comparing once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial. Journal of Opioid Management, 3(1), 35–43.PubMed
39.
Ruoff, G. E., Rosenthal, N., Jordan, D., Karim, R., & Kamin, M. (2003). Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double-blind, placebo-controlled outpatient study. Clinical Therapeutics, 25(4), 1123–1141.CrossRefPubMed
40.
Ueberall, M. A., Eberhardt, A., & Mueller-Schwefe G. H. H. (2016). Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice. International Journal of General Medicine, 9, 39–51.CrossRefPubMedPubMedCentral
41.
Watson, C. P., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003). Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain, 105(1–2), 71–78.CrossRefPubMed
42.
Yarlas, A., Miller, K., Wen, W., et al. (2013). A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. Journal of Pain, 14(1), 14–23.CrossRefPubMed
43.
Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. San Deigo, CA: Academic Press.
44.
Ahn SB, J. B. (2011). Incorporating quality scores in meta-analysis. Journal of Educational and Behavioral Statistics, 36(5), 555–585.CrossRef
45.
46.
EpiGear Internation Pty Ltd. (2015). Meta XL (5.0).
47.
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188.CrossRefPubMed
48.
49.
Sawilowsky, S. (2009). New effect size rules of thumb. Journal of Modern Applied Statistical Methods, 8(2), 597–599.CrossRef
50.
Kraemer, H. C., & Kupfer, D. J. (2006). Size of treatment effects and their importance to clinical research and practice. Biological Psychiatry, 59(11), 990–996.CrossRefPubMed
51.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. New York: Academic Press.
52.
Frich, L. M., Sorensen, J., Jacobsen, S., Fohlmann, B., & Hojsted, J. (2012). Outcomes of follow-up visits to chronic nonmalignant pain patients. Pain Management Nursing: Official Journal of The American Society of Pain Management Nurses, 13(4), 223–235.CrossRef
53.
Sacks, H. S., Chalmers, T. C., & Smith, H. (1982). Randomized versus historical controls for clinical trials. American Journal of Medicine, 72, 233–240.CrossRefPubMed
54.
Schulz, K. F., Chalmers, I., Hayes, R., & Altman, D. G. (1995). Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association, 273, 408–412.CrossRefPubMed
Metadaten
Titel
Health-related quality of life in patients receiving long-term opioid therapy: a systematic review with meta-analysis
verfasst von
J. Douglas Thornton
Rashmi Goyat
Nilanjana Dwibedi
George A. Kelley
Publikationsdatum
02.03.2017
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 8/2017
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1538-0

Weitere Artikel der Ausgabe 8/2017

Quality of Life Research 8/2017 Zur Ausgabe

OriginalPaper

Effect of a comprehensive health education program on pre-hospital delay intentions in high-risk stroke population and caregivers

OriginalPaper

Changes in quality of life after elective surgery: an observational study comparing two measures

OriginalPaper

Health-related quality of life (HRQoL) and its correlates among community-recruited children living with HIV and uninfected children born to HIV-infected parents in West Bengal, India

OriginalPaper

Psychometric validation of the dysmenorrhea daily diary (DysDD): a patient-reported outcome for dysmenorrhea

OriginalPaper

Quality of life independently predicts long-term mortality but not vascular events: the Northern Manhattan Study

OriginalPaper

Development and refinement of the WAItE: a new obesity-specific quality of life measure for adolescents